Show simple item record

dc.contributor.authorSiller, Anita
dc.contributor.authorSeekircher, Lisa
dc.contributor.authorWachter, Gregor A
dc.contributor.authorAstl, Manfred
dc.contributor.authorTschiderer, Lena
dc.contributor.authorPfeifer, Bernhard
dc.contributor.authorGaber, Manfred
dc.contributor.authorSchennach, Harald
dc.contributor.authorWilleit, Peter
dc.date.accessioned2022-04-26T01:02:28Z
dc.date.available2022-04-26T01:02:28Z
dc.date.issued2022-03-09
dc.identifier.issn1999-4915
dc.identifier.other35336975
dc.identifier.otherPMC8954543
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/336438
dc.description.abstractThere is uncertainty about the seroprevalence of anti-SARS-CoV-2 antibodies in the general population of Austria and about the waning of antibodies over time. We conducted a seroepidemiological study between June 2020 and September 2021, enrolling blood donors aged 18-70 years across Tyrol, Austria (participation rate: 84.0%). We analyzed serum samples for antibodies against the spike or the nucleocapsid proteins of SARS-CoV-2. We performed a total of 47,363 samples taken from 35,193 individuals (median age, 43.1 years (IQR: 29.3-53.7); 45.3% women; 10.0% with prior SARS-CoV-2 infection). Seroprevalence increased from 3.4% (95% CI: 2.8-4.2%) in June 2020 to 82.7% (95% CI: 81.4-83.8%) in September 2021, largely due to vaccination. Anti-spike IgG seroprevalence was 99.6% (95% CI: 99.4-99.7%) among fully vaccinated individuals, 90.4% (95% CI: 88.8-91.7%) among unvaccinated individuals with prior infection and 11.5% (95% CI: 10.8-12.3%) among unvaccinated individuals without known prior infection. Anti-spike IgG levels were reduced by 44.0% (95% CI: 34.9-51.7%) at 5-6 months compared with 0-3 months after infection. In fully vaccinated individuals, they decreased by 31.7% (95% CI: 29.4-33.9%) per month. In conclusion, seroprevalence in Tyrol increased to 82.7% in September 2021, with the bulk of seropositivity stemming from vaccination. Antibody levels substantially and gradually declined after vaccination or infection.
dc.languageeng
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101509722
dc.sourceessn: 1999-4915
dc.subjectBlood donors
dc.subjectSeroprevalence
dc.subjectSars-cov-2
dc.subjectAnti-n Igg
dc.subjectAnti-s Igg
dc.subjectHumans
dc.subjectImmunoglobulin G
dc.subjectSeroepidemiologic Studies
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectBlood Donors
dc.subjectAustria
dc.subjectFemale
dc.subjectMale
dc.subjectYoung Adult
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleSeroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021.
dc.typeArticle
dc.date.updated2022-04-26T01:02:27Z
prism.issueIdentifier3
prism.publicationNameViruses
prism.volume14
dc.identifier.doi10.17863/CAM.83855
dcterms.dateAccepted2022-03-07
rioxxterms.versionofrecord10.3390/v14030568
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidTschiderer, Lena [0000-0001-7988-853X]
dc.contributor.orcidWilleit, Peter [0000-0002-1866-7159]
dc.identifier.eissn1999-4915
pubs.funder-project-idTirol Kliniken GmbH (Not available)
pubs.funder-project-idLand Tirol (Not available)
cam.issuedOnline2022-03-09


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International